GSK posts Q3 2026 earnings beat, reaffirms guidance but shares slide on vaccine dip and restructuring charge

GlaxoSmithKline reported third‑quarter 2026 revenue of £8.89 billion, up about 5 % year‑on‑year, and core earnings per share of 54.6 pence, beating analyst forecasts. Core operating profit rose 5 % to roughly £3.08 billion, but statutory profit fell 16 % after a £328 million restructuring charge. The company kept its full‑year 2026 turnover and profit guidance and declared a 17 pence dividend, while its share price dropped 4‑5 % on the market.

Investors saw the earnings beat offset by weaker vaccine sales and the restructuring hit, prompting a 4.6 % fall in GSK shares and a sell rating from Barclays. The reaffirmed guidance means the outlook for turnover growth of 3‑5 % and core profit growth of 7‑9 % remains unchanged for the year.

Sources